Thermosome

Thermosome is a clinical-stage biotechnology company developing a novel, target-agnostic tumor-targeting platform based on thermosensitive liposomes (DPPG2-TSLs). Its lead program, THE001, combines a liposomal doxorubicin formulation with regional hyperthermia to achieve up to 15-fold higher intra-tumoral drug concentration and stimulate an anti-tumor immune response. The company is targeting locally advanced soft tissue sarcoma (LA-STS) as its lead indication, with a Phase I dose escalation study set to conclude in summer 2025, aiming to replace the current standard-of-care doxorubicin with a more effective and potentially curative treatment.

Proprietary thermosensitive liposome (TSL) platform based on DPPG2 phospholipid. Enables heat-triggered, intravascular release of chemotherapeutic drugs within tumors, achieving ~15x higher local concentration. Platform is target-agnostic and combines with regional hyperthermia to stimulate an immune response.

Thermosome competes in the targeted drug delivery and liposomal formulation space. Direct competitors include companies like Celsion (ThermoDox®). Its key differentiation is its patented DPPG2 lipid chemistry, which may offer superior release kinetics, and its focus on combining high local drug concentration with immune stimulation via hyperthermia.